Neurofibromatosis type 1 (NF1) is a rare, lifelong genetic condition that can predispose individuals to tumor development. Among these are NF1-associated plexiform neurofibromas (PNs), infiltrative tumors that can be difficult to treat surgically, cause significant pain,…
Neurofibromatosis type 1 (NF1) is a rare, lifelong genetic condition that can predispose individuals to tumor development. Among these are NF1-associated plexiform neurofibromas (PNs), infiltrative tumors that can be difficult to treat surgically, cause significant pain,…
Discover how the latest breakthroughs in folate receptor alpha (FRα)-targeted antibody-drug conjugates (ADCs) are redefining what’s possible with biomarker-driven therapy! From landmark clinical findings to promising next-generation ADCs, new treatment opportunities are expanding care across the…
Management of neurofibromatosis type 1-associated plexiform neurofibromas (NF1-PNs) has evolved rapidly and now includes indications across age groups. NF1 remains a complex, lifelong condition with diverse and evolving manifestations, requiring clinicians to maintain up-to-date knowledge of…
Management of neurofibromatosis type 1-associated plexiform neurofibromas (NF1-PNs) has evolved rapidly and now includes indications across age groups. NF1 remains a complex, lifelong condition with diverse and evolving manifestations, requiring clinicians to maintain up-to-date knowledge of…
Despite advancements in the treatment of chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) and mantle cell lymphoma (MCL), resistance and recurrence occur frequently and mutations might develop during treatment. Given the diverse range of treatment side effects,…